Acyclovir for treating varicella in otherwise healthy children and adolescents: a systematic review of randomised controlled trials by Klassen, Terry P et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Pediatrics
Open Access BMC Pediatrics  2002,  2 x Research article
Acyclovir for treating varicella in otherwise healthy children and 
adolescents: a systematic review of randomised controlled trials
Terry P Klassen*, Elaine M Belseck, Natasha Wiebe and Lisa Hartling
Address: Alberta Research Center for Child Health Evidence, Department of Pediatrics, University of Alberta, 2C3.00 WMC, Edmonton, Alberta, 
T6G 2R7, Canada
E-mail: Terry P Klassen* - terry.klassen@ualberta.ca; Elaine M Belseck - elaine.belseck@shaw.ca; Natasha Wiebe - nwiebe@ualberta.ca; 
Lisa Hartling - hartling@ualberta.ca
*Corresponding author
Abstract
Background: Acyclovir has the potential to shorten the course of chickenpox which may result
in reduced costs and morbidity. We conducted a systematic review of randomised controlled trials
that evaluated acyclovir for the treatment of chickenpox in otherwise healthy children.
Methods: MEDLINE, EMBASE, and the Cochrane Library were searched. The reference lists of
relevant articles were examined and primary authors and Glaxo Wellcome were contacted to
identify additional trials. Two reviewers independently screened studies for inclusion, assessed
study quality using the Jadad scale and allocation concealment, and extracted data. Continuous data
were converted to a weighted mean difference (WMD). Overall estimates were not calculated due
to differences in the age groups studied.
Results: Three studies were included. Methodological quality was 3 (n = 2) and 4 (n = 1) on the
Jadad scale. Acyclovir was associated with a significant reduction in the number of days with fever,
from -1.0 (95% CI -1.5,-0.5) to -1.3 (95% CI -2.0,-0.6). Results were inconsistent with respect to
the number of days to no new lesions, the maximum number of lesions and relief of pruritis. There
were no clinically important differences between acyclovir and placebo with respect to
complications or adverse effects.
Conclusion: Acyclovir appears to be effective in reducing the number of days with fever among
otherwise healthy children with chickenpox. The results were inconsistent with respect to the
number of days to no new lesions, the maximum number of lesions and the relief of itchiness. The
clinical importance of acyclovir treatment in otherwise healthy children remains controversial.
Background
Varicella, or chickenpox, is a common, highly contagious
illness caused by the varicella-zoster virus (VZV) [1]. It is
primarily a disease of early childhood with 90% of cases
occurring in children 1 to 14 years of age [2]. The disease
spreads by direct person-to-person contact of open lesions
or airborne droplets [1], and tends to increase in severity
with each subsequent case within a household [3]. The pe-
riod of transmission begins one to two days before any
rash appears [4] and continues for the first five to six days
[1]. The disease may be more severe in neonates [5,6],
adults [7], and individuals who have impaired immune
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systems [8,9]. After one episode of varicella, individuals
usually have lifelong immunity [1].
Chickenpox is generally self-limiting in young children
and is manifested by fever, mild constitutional symptoms,
and a pruritic, vesicular rash. Symptoms usually appear
11–20 days after exposure to VZV [2]. The rash most often
appears in three successive crops of lesions numbering on
average 300 to 400 [10]. The lesions progress from mac-
ules through to crusted lesions over a three-day period
[11]. The rash is most commonly distributed over the
trunk, scalp and face. Diagnosis can be made clinically by
the rash characteristic of chickenpox [2] and a history of
contact [1].
Complications of chicken pox are varied and may occur in
5–10% of all patients. Complications among otherwise
healthy children are rare [12,13], but are more common
among neonates, adults and immunocompromised indi-
viduals [2,14]. Data with respect to complication rates
among specific subgroups are lacking. Complications pri-
marily involve the skin, the central nervous system, and
the respiratory system [13,15]. The most frequent compli-
cation is bacterial infection secondary to cutaneous le-
sions [2,13]. The most common neurological
complications are cerebellar ataxia and encephalitis.
Complications of the respiratory system include pneumo-
nia and upper respiratory tract infections (particularly oti-
tis media).
Traditional treatment for chickenpox is symptomatic
through the use of lotions to relieve itchiness [1] and
acetaminophen to reduce fever and pain [4]. Newer treat-
ments include immunoglobulins, vaccines, and anti-viral
drugs for the prevention of chicken pox, as well as immu-
noglobulins and anti-viral drugs to moderate and shorten
the course of the disease. As an anti-viral drug, acyclovir
prevents the replication of the VZV [16,17] and has the
potential to eradicate VZV and relieve symptoms more
rapidly. Since the drug is only absorbed by the cells that
are infected with the virus, acyclovir has minimal adverse
effects [18]. Some reported adverse effects to the oral ad-
ministration of acyclovir include nausea, vomiting, di-
arrhea, and vertigo [18].
The economic burden associated with chickenpox results
from costs associated with hospitalisations, physician vis-
its, prescription and non-prescription medications, and
lost income by caregivers who must remain at home dur-
ing the course of the child's illness [19]. It has been esti-
mated that lost wages account for more than 95% of the
total costs [20]. The U.S. Centers for Disease Control and
Prevention recommend that children remain at home for
six days after the rash onset [10]. These recommendations
vary according to local public health authorities; others
advocate return to normal activity earlier, particularly
with milder forms of the disease [21]. The Canadian Pedi-
atric Society recommends that children return to school as
soon as they feel well enough to resume normal activities,
regardless of the state of the rash [22]. Because of the po-
tential costs associated with lost time from work by prima-
ry caregivers, an intervention that reduces the length of
illness may be well received.
We conducted a systematic review to assess the evidence
on the efficacy of acyclovir in: (a) alleviating symptoms
(number of lesions, pruritis, fever); and, (b) shortening
the duration of the illness. The secondary objective was to
examine complications of chickenpox and adverse effects
associated with acyclovir, as reported in the relevant effi-
cacy trials. This review was conducted in association with
the Acute Respiratory Infections Group of The Cochrane
Collaboration [23].
Methods
A comprehensive search was conducted to identify all rel-
evant studies regardless of language of publication or pub-
lication status. MEDLINE (1966-October 2001), EMBASE
(1988-September 2001), and the Cochrane Controlled
Trials Register (2002, Issue 2) were searched. The refer-
ence lists of all relevant articles were reviewed for addi-
tional studies. A letter was sent to the primary author of
relevant studies as well as the pharmaceutical company
that manufactures acyclovir (GlaxoSmithKline) in order
to identify any other relevant trials. Finally, PubMed was
searched towards the completion of the review to identify
any recent publications (January 2001-April 2002). The
complete search strategies are presented in an additional
file (See Additional File 1: search_strategies.pdf).
The output from the searches was screened independently
by two reviewers (NW, EMB or LH). All potentially rele-
vant studies were retrieved as full manuscripts and then
independently reviewed for inclusion according to estab-
lished criteria. Differences regarding inclusion were re-
solved by consensus reached after discussion. Studies were
included if they: 1) were randomised controlled trials; 2)
evaluated otherwise healthy children 0–18 years of age
who had chickenpox; 3) compared acyclovir to placebo;
4) evaluated at least one objective outcome (i.e., amount
of time to no new lesions, maximum number of lesions,
time to resolution of fever and pruritis, complications,
and adverse events).
All relevant studies were masked by obscuring the authors'
names and institutions, the locations of the study, refer-
ence lists, journal of publication and any other potential
identifiers. Each of the included studies was evaluated for
methodological quality using the previously validated Ja-
dad 5-point scale to assess randomisation (0–2 points),BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/9
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double blinding (0–2 points) and withdrawals and drop-
outs (0–1 point) [24]. Concealment of allocation was de-
scribed as adequate, inadequate or unclear [25]. Two
observers independently assessed quality (NW, TPK). Dif-
ferences were resolved by consensus.
Data were extracted using a structured form that captured
the following information: patient demographics; patient
status (inpatient or outpatient); the intervention (includ-
ing dosage and route of administration); outcomes (i.e.
length of time from randomisation to no new lesions,
crusting, defervescence (i.e. reduction in fever), and cessa-
tion of pruritis); funding source; and, whether the studies
used an intention-to-treat analysis. All complications
from chickpox reported in the studies were recorded. As
well, information on all adverse effects related to the use
of acyclovir was collected. Two reviewers (NW, EMB) ex-
tracted data independently, and results were compared.
Differences were resolved by referring to the original pa-
per.
Data were analysed using Review Manager 4.1 (Cochrane
Collaboration, 2001); Splus 2000 (Insightful Corpora-
tion, 1999) was used for imputations. Continuous data
(e.g., duration of symptoms in days and maximum
number of lesions) were converted to the weighted mean
difference (WMD). Medians were substituted for means
for all outcomes in the study by Balfour et al. [26]. Means
were calculated from proportions of patients remaining
with lesions [27], fever [27,28], and pruritis [27]. Day 5
(fever, pruritis) and day 7 (new lesions) were used as the
last possible day for the event to occur. These substitu-
tions give less conservative estimates of variance. Inter-
quartile ranges were converted into variances [26]. Imput-
ing using upper bound p-values gave conservative varianc-
es in both treatment groups [27,28].
Weighted mean differences were not combined into an
overall estimate due to the varied age groups between
studies. There were too few studies to consider statistical
heterogeneity between studies or to perform subgroup or
sensitivity analyses. Publication bias was also not assessed
for the same reason. Power analyses for complications
were exploratory. Individual study results were pooled
and chi-square tests were the bases of the power analyses.
Since the adverse event data were not independent (the
numbers were reported by event not by patient), risk dif-
ferences could not be calculated, nor any further analysis.
Results
Description of studies
Five hundred and ninety unique references were retrieved.
Eight studies were identified as being potentially relevant.
Four of the studies were excluded because they were not
RCTs [29–32]; one RCT was excluded because it evaluated
immediate versus delayed anti-viral treatment therefore
all patients eventually received acyclovir [33]. Three stud-
ies were included in this analysis [26–28]. There was
100% agreement between the two reviewers with respect
to study relevance.
The three relevant trials are described in Table 1. They
were all conducted in the United States and published in
English. All three studies were placebo-controlled and
evaluated the efficacy of acyclovir among immunocompe-
tent children in an outpatient setting.
Methodological quality of included studies
The quality scores of included studies, as measured by the
Jadad scale, were four in one trial [26] and three in the re-
maining two trials [27,28]. All three studies were de-
scribed as being randomised and double-blinded. Only
one trial described a detailed and appropriate method of
randomisation [26]. One trial [26] described an appropri-
ate method of double-blinding. Two of the three trials ad-
equately discussed withdrawals [27,28]. Allocation
concealment was unclear in all three trials. Two studies
[27,28] performed intention-to-treat analyses on adverse
events and on a select few of the remaining outcomes. All
three studies received pharmaceutical sponsorship. In ad-
dition, two studies received financial support from other
external sources [26,28].
Primary outcome: number of days to no new lesions
Two of the studies found a statistically significant advan-
tage to taking acyclovir (figure 1). The number of days to
no new lesions was reduced by 1.2 (95% CI -1.5,-1.0) and
1.1 days (95% CI -1.8,-0.5), respectively [27,28]. The third
study found no statistically significant difference (0 days;
95% CI-0.5,0.5) [26].
Additional outcomes
The results with respect to the maximum number of le-
sions appeared to be homogeneous, however, only two of
three studies reported a significant difference favouring
treatment with acyclovir (figure 2). The WMDs ranged
from -24 (95% CI -74,26) [28] to -164 (95% CI -228,-
100) [26].
The number of days to no fever was reduced by treatment
with acyclovir in all three trials: -1.1 days (95% CI-1.3,-
0.9), -1.0 (95% CI -1.5,-0.5), and -1.3 (95% CI -2.0,-0.6)
[27,26,28] (figure 3).
The number of days to relief of pruritis was reported in
two studies: Dunkle et al. found a 0.8 day advantage with
acyclovir treatment (95% CI -1.0,-0.7) [27] and Balfour et
al., found no advantage (0 days; 95% CI -0.6,0.6) [26]
(figure 4).BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/9
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Figure 1
Metagraph of Acyclovir versus Placebo: time to no new lesions
Table 1: Characteristics of randomised controlled trials comparing acyclovir to placebo among immunocompetent children
Study Number of participants Age Range 
(mean)
Acyclovir protocol Outcomes Quality
Total Per group Jadad 
Score
Allocation 
Concealment
Balfour 
1990
102 50 – acyclovir
50 – placebo
5–16 years 
(8.1)
5–7 years: 20 mg/kg
7–12 years: 15 mg/kg
12–16 years: 10 mg/kg
4x/days for 5-7 days
• Days to fever, crusting, no
new lesions, maximum number
 of lesions, decrease in number
 of lesions and cessation of
itching
• Maximum number of lesions
4U n c l e a r
Dunkle 
1991
815 408 – acyclovir
407 – placebo
2–12 years 
(5.2)
20 mg/kg 4/day for 5 
days
• Maximum number of lesions
• Number with >500 lesions
• Residual lesions at day 28
3U n c l e a r
Balfour 
1992
62 31 – acyclovir
31 – placebo
13–18 years 
(14.8)
800 mg 4/day for 5 
days
• Days to maximum number of
 lesions and cessation of
 itching
• Maximum number of lesions
• Residual lesions at day 28
3U n c l e a rBMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/9
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Figure 2
Metagraph of Acyclovir versus Placebo: maximum number of lesions
Figure 3
Metagraph of Acyclovir versus Placebo: time to no feverBMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/9
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The earlier Balfour study [26] results were imputed from
non-parametric data and may have produced less precise
results. If so, this may indicate a stronger advantage for
taking acyclovir in the number of days to no new lesions
and relief of itching. This might also indicate a smaller ad-
vantage for taking acyclovir in reducing the maximum
number of lesions.
Adverse effects
Reported adverse effects related to the use of acyclovir in-
volving the gastrointestinal system included: anorexia (23
acyclovir; 30 placebo); diarrhea (25 acyclovir; 18 place-
bo); nausea/vomiting (11 acyclovir; 10 placebo); stomach
ache/abdominal pain (22 acyclovir; 14 placebo); flatu-
lence (2 acyclovir; 4 placebo). Those involving the respi-
ratory system included: coryza (18 acyclovir; 23 placebo);
cough (23 acyclovir; 29 placebo); ear pain/redness (5 acy-
clovir; 6 placebo); sore throat (24 acyclovir; 33 placebo).
The following adverse effects involving the skin were not-
ed: hives (1 acyclovir; 1 placebo); rash, other than varicel-
la (3 acyclovir; 1 placebo). Other reported effects were:
conjunctivitis (acyclovir 8; placebo 11); headache (acyclo-
vir 21; placebo 22); malaise (acyclovir 25; placebo 28); ir-
ritability (acyclovir 1); skin odour (acyclovir 1); insomnia
(acyclovir 5; placebo 5); nose bleed (acyclovir 2; placebo
1); dizziness (acyclovir 3; placebo 2); restlessness (acyclo-
vir 1; placebo 1); arthralgia (placebo 3); frequency (place-
bo 1); night sweats (placebo 1); hyperkinesias (acyclovir
1; placebo 1); pain (acyclovir 1); spasmodic hand move-
ments (acyclovir 1; placebo 1).
Complications
Complications from chickenpox were grouped by those
involving the skin, central nervous system, or respiratory
system (figure 5). Fifteen patients developed secondary
bacterial skin infections (5 acyclovir; 10 placebo). Central
nervous system complications included cerebellar ataxia
(1 placebo) and meningoencephalitis (1 placebo). Respi-
ratory ailments included pneumonia (1 acyclovir), otitis
media (2 acyclovir; 4 placebo), pharyngitis (2 acyclovir; 2
placebo), and bronchitis (1 acyclovir). There were no sig-
nificant differences between the treatment groups with re-
spect to all the grouped complications arising from
chickenpox. Skin complications gave the largest simply
pooled difference at 1%. The review is not sufficiently
powered to detect this difference, however, the size of dif-
ference is not deemed clinically important. The central
nervous system and respiratory simply pooled differences
were less than 0.5%.
Discussion
This systematic review of acyclovir for the treatment of
chickenpox in otherwise healthy children supports a re-
duction in disease severity and a shorter course of disease.
Figure 4
Metagraph of Acyclovir versus Placebo: time to no pruritisBMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/9
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This is demonstrated by a one-day reduction in the
number of days with fever. Results were inconsistent,
however, with respect to the number of days to no new le-
sions, the maximum number of lesions and the number
of days to relief of pruritis. The results for the earlier Bal-
four study [26] were imputed from non-parametric data
and may therefore be less precise possibly strengthening
the evidence that supports the use of acyclovir in other-
wise healthy children. There were no clinically important
differences between acyclovir and placebo with respect to
complications associated with chickenpox or adverse ef-
fects associated with the drug.
The quality of the included studies was relatively good as
measured by the Jadad scale, thus having a low risk of bias
in the studies' conduct. However, caution is heeded when
interpreting the results given that all studies had pharma-
ceutical sponsorship and some of the authors were affili-
ated with the original manufacturer of acyclovir. Research
has shown that study conclusions are associated with au-
thors' affiliations [34,35] and that studies with pharma-
ceutical sponsorship are more likely to have outcomes
favouring the drug under study [36].
We identified only three studies relevant to this review.
These studies were heterogeneous in that each studied a
different age group. Because of the small number of stud-
ies and their different study populations, we did not feel
that it was appropriate to provide overall estimates of effi-
cacy. Publication bias was also not assessed because of the
small number of trials.
Although these studies have demonstrated the efficacy of
acyclovir, the clinical importance of acyclovir treatment in
otherwise healthy children remains controversial. The de-
bate in the literature features four common themes:
First, the treatment appears to confer at best modest ben-
efits for a disease that is self-limiting and has few compli-
cations in otherwise healthy children [13,19].
Second, trials have demonstrated acyclovir to be effica-
cious when treatment was initiated within 24 hours of
rash onset. Various authors have criticized this as being
impractical in that many patients may not detect disease
onset, and obtain a prescription until well after this 24-
hour window [15,19,37]. In a recent trial Balfour et al.
showed that patients who initiated acyclovir within 24
hours of rash onset showed better clinical response to
therapy compared to those who initiated treatment at 48
or 72 hours [33]. Further, patients who began therapy af-
ter 48 hours responded more favourably than those who
Figure 5
Metagraph of Acyclovir versus Placebo: complications Complications are grouped as skin, CNS and respiratory.BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/9
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started after 72 hours. Others have questioned the extent
of compliance in practice with the treatment regimens
that have been studied (i.e., four doses per day) [37,38].
Alterations in compliance may dilute already moderate re-
sults [19].
Third, while no formal cost-benefit analysis has been con-
ducted, various critics have suggested that treatment ben-
efits do not justify the additional costs of the drug as well
as the physician visits required to obtain a prescription
[13,37,38]. If treatment with acyclovir does not signifi-
cantly alter the complication rate of varicella, then the rate
of hospitalisations, and their associated costs, is unlikely
to change [36]. In addition, only one study specifically
measured the impact of acyclovir treatment on school at-
tendance [26]. This study found no difference in the
number of days missed from school between the acyclovir
and placebo groups. Treatment with acyclovir may not
have a substantial impact on the number of days missed
from school as public health authorities in some jurisdic-
tions move towards more permissive policies regarding
school attendance following VZV infection [22].
Finally, concerns have been raised regarding the emer-
gence of an acyclovir resistant strain of VZV [13,37–39].
There is evidence to suggest that resistant strains of VZV do
not occur [33,40,41].
At present, there appear to be too many unanswered ques-
tions to advocate the widespread use of acyclovir in other-
wise healthy children. The treatment of chickenpox with
acyclovir may become immaterial as public health author-
ities worldwide move towards adopting the varicella vac-
cine to protect against VZV [10,15].
This review has raised questions for further research. First
a comprehensive cost-benefit analysis is required. Second,
there were few data available on the impact of acyclovir
on the number of days missed from school or work. If one
of the more important advantages of acyclovir is to allow
individuals to return to their activities sooner, this needs
to be specifically evaluated and documented. Third, there
is no evidence regarding different doses of acyclovir treat-
ment. Smaller doses may reduce costs and increase com-
pliance. Fourth, further research needs to focus on the
identification and treatment of immunocompetent chil-
dren who are at higher risk of more severe diseases such as
children with chronic respiratory conditions or children
exposed through intrafamilial contact. Finally, other anti-
virals against varicella with improved bioavailability are
now available (i.e., valaciclovir and famciclovir) and need
to be studied in pediatric populations.
Conclusions
When initiated within 24 hours of rash onset, treatment
with acyclovir shows a therapeutic benefit by reducing the
length of time with fever in immunocompetent children.
However, the results are inconsistent with respect to the
number of days to no new lesions, the maximum number
of lesions and relief of pruritis. The existing evidence does
not support the widespread use of acyclovir among young
immunocompetent children in which chickenpox is self-
limiting and results in few complications.
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